SCHEMBL3343494

SCHEMBL3343494

COC(=O)NCCOC(c1ccccc1)c1cccc(C(=O)OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 2/20 0.49
HTR1A P08908 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
HTT P42858 1/20 0.44
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.42
SLC7A5 Q01650 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
HPGD P15428 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
PARP1 P09874 1/20 0.41
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643578 0.92 CASR (0.42) CASRHTR1AADRA1DADRA1AADRA1B
SCHEMBL8076505 0.91 HTR1A (0.46) CASRHTR1AADRA1DADRA1AADRA1B
SCHEMBL3344191 0.91 CASR (0.42) CASRSLC7A5LOXL2PARP1CYP4F2
SCHEMBL3338753 0.90 HTR1A (0.46) CASRHTR1AADRA1DADRA1AADRA1B
SCHEMBL1568426 0.90 ADRB2 (0.47) CASRHTTTSHRRAB9AHPGD
Lithium Ion SCHEMBL3338747 0.88 HTR1A (0.44) CASRHTR1AADRA1DADRA1AADRA1B
SCHEMBL3341708 0.84 ADRB2 (0.41) CASRHTTTSHRRAB9ACYP3A4
SCHEMBL10068808 0.84 HTT (0.43) HTTTSHRRAB9AHPGDCYP3A4
SCHEMBL3343678 0.84 LOXL2 (0.50) CASRHTR1AADRA1DADRA1AADRA1B
SCHEMBL3641253 0.83 ALDH1A1 (0.41) CASRHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
EP-2170815-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2010-04-07 EP disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160424-A1 RENIN INHIBITORS ACE, REN, DNPEP CASR 1270/4885HTR1A 3341/4885ADRA1D 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.